Amgen taps Jonathan Peacock as chief financial officer, replacing interim CFO Michael Kelly

Amgen names Peacock chief financial officer

THOUSAND OAKS, Calif. — Biotechnology company Amgen Inc. said Thursday it named Novartis executive Jonathan M. Peacock as its new chief financial officer.

Peacock succeeds Michael A. Kelly, 53, who has served as acting chief financial officer since May. In April, the company named then CFO Robert A. Bradway to the newly created position of chief operating officer.

Peacock, 52, joins Amgen from Swiss drugmaker Novartis Pharmaceutical AG, where he served as chief financial officer and administration officer since 2005. Prior to the Novartis position, he was a partner at consulting firm McKinsey & Co. He was also a partner at Price Waterhouse in New York and London.

Amgen said in a regulatory filing Peacock will receive an annual salary of $800,000 and is eligible to participate in the company’s management incentive plan, with an incentive target of 80 percent of his base compensation. He will receive a $1 million sign-on bonus and grants of 100,000 restricted stock units and 175,000 stock options.

He also receives a relocation package worth up to $400,000.

Kelly will relocate to Zug, Switzerland to serve as Amgen’s vice president of international finance.

The appointments are effective Sept. 1.

Shares of Thousand Oaks, Calif.-based Amgen rose 8 cents to $52.70 in afternoon trading.